Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

328 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor.
Zanotti R, Ambrosetti A, Lestani M, Ghia P, Pattaro C, Remo A, Zanetti F, Stella S, Perbellini O, Prato G, Guida G, Caligaris-Cappio F, Menestrina F, Pizzolo G, Chilosi M. Zanotti R, et al. Among authors: pizzolo g. Leukemia. 2007 Jan;21(1):102-9. doi: 10.1038/sj.leu.2404458. Epub 2006 Nov 2. Leukemia. 2007. PMID: 17082778
The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis.
De Matteis G, Zanotti R, Colarossi S, De Benedittis C, Garcia-Montero A, Bonifacio M, Sartori M, Aprili F, Caruso B, Paviati E, Carli G, Perbellini O, Zamò A, Bonadonna P, Pizzolo G, Guidi G, Martinelli G, Soverini S. De Matteis G, et al. Among authors: pizzolo g. Leuk Res. 2015 Mar;39(3):273-8. doi: 10.1016/j.leukres.2014.11.029. Epub 2014 Dec 6. Leuk Res. 2015. PMID: 25582384
Biopathologic features of Hodgkin's disease.
Chilosi M, Pizzolo G. Chilosi M, et al. Among authors: pizzolo g. Leuk Lymphoma. 1995 Feb;16(5-6):385-95. doi: 10.3109/10428199509054424. Leuk Lymphoma. 1995. PMID: 7787748 Review.
Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin.
Todeschini G, Tecchio C, Meneghini V, Pizzolo G, Veneri D, Zanotti R, Ricetti MM, Solero P, April F, Perona G. Todeschini G, et al. Among authors: pizzolo g. Leukemia. 1998 Feb;12(2):144-9. doi: 10.1038/sj.leu.2400912. Leukemia. 1998. PMID: 9519775 Clinical Trial.
328 results